D1SportsNetwork Launches TourneyManager to Simplify Event Management and Eliminate Traditional Fees
SimpleEquity Launches Suite of Collaborative Financial Tools for Separation, Divorce and Estate Planning
Data I/O Announces Significant Direct Investment to Support The NEW Data I/O
QCI Completes VizExplorer Customer Transition in Under a Year, Marking Major Platform Unification Milestone
IC Manage GDP-AI Transforms IP Lifecycle Management with Generative and Agentic AI
Company Provides Comprehensive Clinical Update from Phase 1/2 Trial Tuspetinib Continues to Deliver Single Agent…
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate…
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis)…
The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and…
— Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed…
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and…
Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and…
Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib…
Data from REDIRECT establish that AFM13 monotherapy is effective in the treatment of relapsed/refractory peripheral…
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose…
AFM13 in combination with NK cells shows very high overall and complete response rates in…
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in…
Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium,…
With nearly four years of study follow-up, all-oral, fixed-duration IMBRUVICA® (ibrutinib) + venetoclax reduced the…
Results from the pivotal MonumenTAL-1 study, including first results from the Phase 2 portion, featured…
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this…
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML ––…
– A total of 17 pediatric patients were treated with STRO-002 on a compassionate use…
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts UTRECHT,…
-Participants with SR-aGVHD disease achieved an ORR of 67% and CR of 17% as measured…